Description: BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, RPMI 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was founded in 1944 and is based in Lublin, Poland.
Home Page: biomedlublin.com
ul. Uniwersytecka 10
Lublin,
20-029
Poland
Phone:
48 81 533 82 21
Officers
| Name | Title |
|---|---|
| Mr. Waldemar Sierocki | Sec. of Supervisory Board & Member of Supervisory Board |
| Mr. Mieczyslaw Starkowicz | Pres of the Management Board & CEO |
| Radoslaw Wroblewski | Chief Financial Officer |
| Mr. Jakub Winkler | Chief Organizational & Legal Officer and Member of the Management Board |
| Ms. Katarzyna Krukowoska | Chief Accountant |
Exchange: WAR
Country: PL
Currency: Polish złoty (zł)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 62.5 |
| Price-to-Book MRQ: | 4.8221 |
| Price-to-Sales TTM: | 7.4003 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |